Released Nov 8, 2022, after the close
10-Q filed Nov 8, 2022, 39 days after period end · 0000950170-22-023279
Q3 2022 · 10-Q
Revenue$25.15M$25.15M +195.3% vs Q3 2021−10.5% vs Q2 2022
Net Income-$19.49M-$19.49M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.37-$0.37 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$21,210,000N/M
Operating Cash Flowderived$65,854,000N/M
Margins · derived
Operating margin-84.3%+322.8 pt vs Q3 2021
Net margin-77.5%+285.3 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $25.15M | $8.52M | $17.82M | $12.28M |
| Net Income | -$19.49M | -$30.90M | $17.14M | -$12.91M |
| EPS Diluted | -$0.37 | -$0.67 | $0.45 | -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR